Development of non-face-to-face marketing tools, bold facility investment,’Crisis as an opportunity’ in preparation for the post coronavirus
[의학신문·일간보사=김영주 기자]It is read that Korea United Pharmaceutical’s 2021 will focus on changing’crisis into opportunity’ in preparation for the post-corona era on the basis of being a strong player in’improved new drugs’. While pursuing growth through continuous development of improved drugs and sales expansion, the company is taking the development of non-face-to-face marketing tools and bold facility investment as its main management strategies.
“In 2021 of Korea United Pharm, as in previous years, growth through improved new drugs is the core management goal. Increasing R&D and sales of improved drugs will naturally accelerate the company’s growth.”
 |
Deok-young Kang, president of Korea United Pharmaceuticals, who became a new drug evangelist with the will to challenge innovative new drugs by breaking away from generics and accumulating capabilities with improved new drugs (Photo)’S 2021 management vision.
President Kang Deok-young said, “We plan to continue to increase the proportion of improved new drugs. To date, we have launched 12 improved drugs and improved products, accounting for about 38% of sales. We plan to increase the proportion of sales every year to 50%.”
Korea United Pharm’s blockbuster antithrombotic drug’Silostan CR tablet’ (2020 sales of 37.2 billion won) and indigestion treatment’Gastine CR tablet’ (2020 sales of 19.3 billion won) continue to show power in the market. In addition, the hypertriglyceridemia treatment’Omethyl Cutielet’ (2020 sales of 3.5 billion won), which was released at the end of 2019, is also receiving a good response.
|
Current status of major improved drug performance (Unit: KRW 100 million) |
 |
In addition, new products are released and existing products are upgraded. A total of 20 candidates for improved drugs are under development, and at the beginning of this year, a new drug combination drug for hyperlipidemia,’Atromac Combigel’, was approved and put on the market. In addition, the market is expected to expand as upgrades such as diversification of the capacity of existing improved drugs and simplification of formulations are prepared.
President Kang Deok-young said, “Like last year, we will continue to increase our lineup of new products by investing more than 12 percent of sales in R&D. We are preparing to release various improved drugs in the fields of circulatory and endocrine, digestive and respiratory systems. He said.
In the export sector, we plan to continuously increase the proportion of improved new drugs. United Pharmaceutical plans to continue its online and offline overseas business based on various government support projects such as global support for mid-sized companies, emergency branch offices, and video conferences for follow-up missions for economic diplomacy. As of 2020, the proportion of exports was about 60.7% of anticancer drugs, about 7% of anti-inflammatory and analgesic drugs, about 6.8% of antibiotics, and about 3.7% of the circulatory system.
Korea United Pharmaceutical is also taking steps to develop new drugs. Currently, clinical trials such as the new natural anticancer drug’PLK-1 inhibitor’ and’Non-alcoholic steatohepatitis (NASH) treatment’ are under clinical trials, and future technology exports to global pharmaceutical companies are planned. President Kang Deok-young said, “We are also pursuing our own way of developing new drugs,” and said, “First of all, we will sell domestically and look for side effects, and if we are confident, we will take the steps to enter global markets such as the United States.”
“There is a situation where many companies can contract due to Corona 19, but United Pharmaceutical will prepare for a new order after Corona 19 with bold investments.”
In a situation where it is not easy to do face-to-face business due to Corona 19, Korea United Pharmaceutical is preparing a countermeasure through web symposium, brochure QR code insertion, and online marketing tool development.
United Pharmaceuticals is planning to expand facility investment, especially for the future. With a new investment, it is preparing to operate an anticancer drug-only plant in Sejong 2 Plant. Currently, it is in the process of completing the construction of internal facilities and aims to obtain advanced GMP certification such as cGMP. Through this, it is determined to become a global anticancer drug company. In addition, an automated logistics warehouse will be completed at Sejong Plant 1. In the future, all logistics produced will be automatically classified, increasing the efficiency of the process.
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>